The company’s earnings before interest, taxes, depreciation and amortisation (EBITDA) increased 17.3% year-on-year to ₹28.8 crore from ₹24.5 crore, while EBITDA margin expanded to 17.4% from 16.5%, indicating an improvement in operating profitability.
On a sequential basis, profit after tax from continuing operations stood at ₹13.9 crore, compared with a loss of ₹19.4 crore in the March quarter. The preceding quarter included an exceptional expense of ₹33.2 crore related to the reversal of income recognised in an earlier year. Revenue from operations increased 8.2% from ₹153.1 crore in the March quarter to ₹165.6 crore.
Profit before tax came in at ₹16.5 crore, compared with a loss before tax of ₹20.8 crore in the previous quarter. The March quarter included an exceptional expense of ₹33.2 crore, primarily due to the reversal of income recognised in an earlier period under a technical know-how arrangement after delays linked to geopolitical instability in the West Asia.
Also read: Rallis India Q1 profit rises 32% as margins improve on broad-based growth
Bajaj Healthcare operates in the pharmaceuticals segment, manufacturing active pharmaceutical ingredients, formulations and nutraceutical products. Shares of the company closed at ₹391, up 4.56% from the previous close, on the National Stock Exchange.
